Host Biomarker Panel for Tuberculosis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tools for tuberculosis (TB) are inadequate for early diagnosis and monitoring treatment response, especially in resource-poor settings, due to limitations such as unavailability, high costs, and inability to distinguish between live and dead bacteria, and existing immunodiagnostic tests are not suitable for point-of-care in resource-constrained environments.
Innovation Solution
A method using a panel of biomarkers, including neural cell adhesion molecule (NCAM) and other markers like ferritin, SAP, and IL-1β, detected in unstimulated blood samples to diagnose TB and differentiate it from latent infection, employing capture agents and indicators for accurate detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If culture-based assays (gold standard) are used for TB diagnosis, then diagnostic accuracy is improved, but availability and accessibility deteriorate due to unavailability in resource-poor settings and long turn-around time
Solution Approach 1:
The invention extracts the diagnostic function from complex culture-based systems to simpler immunodiagnostic tests that detect host immune responses (cytokines, antibodies, antigens) directly from patient samples. This extraction enables diagnosis without requiring sophisticated laboratory infrastructure, making it accessible in resource-poor settings while maintaining diagnostic accuracy through detection of specific immune markers associated with active TB.
2Speed
If Xpert MTB/RIF test is used for TB diagnosis, then diagnostic speed and resistance detection are improved, but operating costs and infrastructure requirements worsen
Solution Approach 1:
The invention employs disposable immunodiagnostic test devices (such as lateral flow assays, microplate ELISA kits) that detect TB-specific immune markers without requiring expensive molecular diagnostics infrastructure. These single-use devices eliminate the need for sophisticated laboratory equipment, trained personnel for complex operations, and expensive reagents, while providing rapid results at lower operational costs suitable for resource-constrained environments.
3Ease of operation
If smear microscopy is used for monitoring TB treatment response, then simplicity is improved, but ability to distinguish live from dead bacilli deteriorates
Solution Approach 1:
The invention introduces host immune markers (cytokines, antibodies, antigens) as intermediary indicators that reflect the presence of viable, metabolically active bacteria. Instead of directly observing bacteria (which cannot distinguish live from dead), the test detects immune responses that only occur in the presence of living pathogens, thereby providing indirect but accurate monitoring of treatment response while maintaining operational simplicity.
4Measurement precision
If IGRAs are used for TB diagnosis, then detection of MTB infection is improved, but ability to discriminate active disease from latent infection deteriorates
Solution Approach 1:
The invention segments the immune response into multiple distinct marker categories (pro-inflammatory cytokines like IL-6, TNF-alpha; antibodies against specific antigens; soluble antigens) that reflect different aspects of TB pathology. By measuring multiple segmented markers simultaneously, the test can distinguish the immune profile of active disease (with specific cytokine patterns and antibody responses) from latent infection (with different marker profiles), thereby recovering the discriminatory information lost in single-marker IGRAs.
5Measurement precision
If overnight culture-based assays are used for immunodiagnosis, then diagnostic capability is improved, but suitability for point-of-care deteriorates
Solution Approach 1:
The invention employs pre-coated solid-phase capture agents (antibodies, antigens) on test devices that are prepared in advance. When patient samples are applied, the pre-positioned capture agents immediately bind target immune markers without requiring overnight incubation or complex preparation steps. This preliminary positioning of diagnostic elements enables rapid point-of-care testing while maintaining the diagnostic capability of detecting specific TB-related immune responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid, cost-effective, and accurate diagnosis of TB, distinguishing active TB from latent infection, and potentially monitoring treatment response, suitable for point-of-care in resource-poor settings using a kit or device for blood sample analysis.
Implementation Method 1
employing capture agents and indicators for accurate detection
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method of diagnosing tuberculosis disease (TB) is provided. A blood sample from a subject is tested for NCAM and optionally also for other biomarkers such as ferritin, SAP, A2M, IL-22, CFH, ECM-1, IL-1 β, sCD4DL,IL-13, Apo-A-1, myoglobin, IL-12(p40), MIP-4, antithrombin III, GDF-15 and HCC1. A device and kit for performing the method are also provided.